Piper Sandler Maintains Overweight on Aptose Biosciences, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Aptose Biosciences (NASDAQ:APTO) but lowers the price target from $37 to $12.
August 11, 2023 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Aptose Biosciences but lowered the price target from $37 to $12.
The lowering of the price target by Piper Sandler from $37 to $12 indicates a potential decrease in the short-term value of Aptose Biosciences' stock. This could lead to a negative impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100